title: Ipilimumab and its toxicities: a multidisciplinary approach.
abstract: The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.
authors.affiliation: University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, USA. lafecher@iu.edu
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Fecher
authors.forename: Sanjiv S
authors.initials: SS
authors.lastname: Agarwala
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Weber
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D060908:CTLA-4 Antigen / Q000276:immunology / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology*; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D053218:Receptors, Death Domain / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D053218:Receptors, Death Domain
keywords: AEOSI; Antibody; CTLA-4; Immune-mediated toxicity; Ipilimumab; Melanoma; immune-related adverse events